Traveler’s Diarrhea Treatment Market by Drug Class, Pathogen and Forecast to 2027

Traveler’s Diarrhea Treatment Market Traveler’s Diarrhea Treatment Market Segmentation by Drug Class: Oral Rehydration Therapy (ORS), Antidiarrheal Agents, Antibiotics [Azithromycin, Ciprofloxacin, Quinolones, and Rifaximi], Vaccines/Prophylactics, and Others; Pathogen: Bacteria [E. Coli, Salmonella Spp, and Others], Viruses, and Protozoa; Age Group: Adults and Children; and Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies, Forecast, 2019 - 2027

©2019 Transparency Market Research, All Rights Reserved

Table of Content Sr. No.

Content

Chapter 1

Preface

Chapter 2

Assumptions and Research Methodology

Chapter 3

Executive Summary : Global Traveler’s Diarrhea Treatment Market

Chapter 4

Market Overview

Chapter 5

Global Traveler’s Diarrhea Treatment Market Analysis and Forecast, by Drug Class

Chapter 6

Global Traveler’s Diarrhea Treatment Market Analysis and Forecast, by Pathogen

Chapter 7

Global Traveler’s Diarrhea Treatment Market Analysis and Forecast, by Age

Chapter 8

Global Traveler’s Diarrhea Treatment Market Analysis and Forecast, by Distribution Channel

Chapter 9

Global Traveler’s Diarrhea Treatment Market Analysis and Forecast, by Region

Chapter 10

North America Traveler’s Diarrhea Treatment Market Analysis and Forecast

Chapter 11

Europe Traveler’s Diarrhea Treatment Market Analysis and Forecast

Chapter 12

Asia Pacific Traveler’s Diarrhea Treatment Market Analysis and Forecast

Chapter 13

Latin America Traveler’s Diarrhea Treatment Market Analysis and Forecast

Chapter 14

Middle East & Africa Traveler’s Diarrhea Treatment Market Analysis and Forecast

Chapter 15

Competition Landscape ©2019 Transparency Market Research, All Rights Reserved

Traveler’s Diarrhea Treatment Market - Snapshot

Traveler’s diarrhea is a stomach and intestinal infection caused due to a bacterial, viral or protozoal infection. It is commonly caused due to a bacterial infection.

Antidiarrheal agents are the first line treatment for traveler’s diarrhea and are used for mild, moderate, and severe diarrhea caused while travelling.

The risk of traveler’s diarrhea is low in developed countries such as the U.S., Australia, New Zealand, Japan, and those in Europe.

©2019 Transparency Market Research, All Rights Reserved

Report Highlights The Global traveler’s diarrhea treatment market expected to reach a value of ~US$ 1.3 Bn by 2027.

is

The traveler’s diarrhea treatment market is expanding at a rapid pace, as awareness among travelers related to ill effects of traveler’s diarrhea is increasing.

Antibiotic prophylaxis is used to prevent traveler’s diarrhea, which is primarily caused by bacterial etiologies.

Industry players are focused on R&D to introduce new therapeutic products for the treatment of traveler’s diarrhea.

Request For Sample ©2019 Transparency Market Research, All Rights Reserved

Continue..

Key players are expanding their footprint to strengthen their position in the global traveler’s diarrhea treatment market.

Prominent players operating in the global traveler’s diarrhea treatment market are Johnson & Johnson (Johnson & Johnson Consumer Inc.), Bausch Health Companies Inc. The goal of pre-travel consultation is to improve the understanding of travelers about travel-related health hazards and diseases.

Request For Brochure

©2019 Transparency Market Research, All Rights Reserved

Contact

To know more about us, please visit our website:

www.transparencymarketresearch.com For sales queries or new topics email us on:

sales@transparencymarketresearch.com

Thank You

Š2019 Transparency Market Research, All Rights Reserved